Full Press Release Details
"With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators and instruments," commented Will Geist , President of Bio-Techne's Protein Sciences Segment. "Leo will enable our customers to accelerate their cutting-edge science and bring next generation therapies to market faster."
Early adopters have been thrilled with the power that Leo brings, with beta testers praising the instrument's robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays, recombinant protein expression and more.
Explore Leo's capabilities at bio-techne.com/leo . Data on Leo's performance will be presented at an upcoming webinar. Registration details can be found here.
About Bio-Techne Corporation (NASDAQ: TECH ) Contact: David Clair , Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416
SOURCE Bio-Techne Corporation